Profilo
Paul Rivard is currently the VP-Operations & General Counsel at MyMD Pharmaceuticals (Florida), Inc. Previously, he held the position of President & General Counsel at MIRA Pharmaceuticals, Inc. He also served as the Chief Legal Officer & Vice President-Operations at TNF Pharmaceuticals, Inc. from 2021 to 2023.
Mr. Rivard completed his undergraduate degree at Clarkson University in 1992 and obtained his graduate degree from Columbus School of Law in 1998.
Posizioni attive di Paul Rivard
| Società | Posizione | Inizio |
|---|---|---|
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Direttore operativo | - |
Precedenti posizioni note di Paul Rivard
| Società | Posizione | Fine |
|---|---|---|
| Q/C TECHNOLOGIES, INC. | Direttore operativo | 14/11/2023 |
| MIRA PHARMACEUTICALS, INC. | Presidente | - |
Formazione di Paul Rivard
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Clarkson University
Clarkson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbus School of Law
Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Health Technology |
MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan | Health Technology |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
















